Media/Policy Watch

Media/Policy Watch
This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. Media Watch is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers, magazines and blog sources, and is segregated from Journal Watch above which scans the peer-reviewed journal ecology.
We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.


The Atlantic
Accessed 28 Nov 2020
Your Individually Rational Choice Is Collectively Disastrous
Stopping the virus from spreading requires us to override our basic intuitions.
November 24, 2020
Yascha Mounk
.. Many factors help explain America’s abject failure to contain the pandemic. A good number of them can be traced back to Donald Trump. But many democracies with able leaders, such as Germany and Canada, are also struggling to contain the virus, so pointing to the president’s lies and incompetence isn’t sufficient.
One major problem is that stopping the virus from spreading requires us to override our basic intuitions. Three cognitive biases make it hard for us to avoid actions that put us in great collective danger…


Accessed 28 Nov 2020
[No new, unique, relevant content]


The Economist
Accessed 28 Nov 2020
United States Nov 28th 2020 edition
America will be the first country to roll out a covid-19 vaccine
Here is how the federal government and states plan to do it


Financial Times
Accessed 28 Nov 2020
Coronavirus treatment
UK set to approve Pfizer-BioNTech Covid vaccine within days
…The UK is poised to become the first western country to approve a Covid-19 vaccine, with the independent regulator set to grant approval within days. Deliveries of the vaccine developed by BioNTech…
November 28, 2020

Analysis Pharmaceuticals sector
Covid vaccines offer Big Pharma a chance of rehabilitation
November 27, 2020

Analysis Coronavirus treatment
How AstraZeneca and Oxford found their vaccine under fire
ovember 27, 2020


Accessed 28 Nov 2020
Breaking  |  5 hours ago
Biden Creates Diverse Covid-19 Advisory Board To Contrast With Trump
Trump’s task force is primarily composed of political appointees with portfolios ranging from the economy to national security to housing.
By Andrew Solender Forbes Staff


Foreign Affairs
Accessed 28 Nov 2020
[No new, unique, relevant content]


Foreign Policy
Accessed 28 Nov 2020
[No new, unique, relevant content]


The Guardian
Accessed 28 Nov 2020
[No new, unique, relevant content]


New Yorker
Accessed 28 Nov 2020
[No new, unique, relevant content]


New York Times
Accessed 28 Nov 2020
Britain Set to Leap Ahead in Approving Vaccines
Regulators may approve the troubled AstraZeneca vaccine and the American-made Pfizer shot weeks before the U.S. does so.
By Benjamin Mueller Nov. 27

The military’s role in a vaccine will be strictly behind the scenes, despite Trump’s claims.
By Jennifer Steinhauer Nov. 27

The Virus Won’t Stop Evolving When the Vaccine Arrives
The coronavirus is not a shape shifter like the flu virus, but it could become vaccine resistant over time. That prompts researchers to urge vigilance.
By James Gorman and Carl Zimmer Nov. 27

After Admitting Mistake, AstraZeneca Faces Difficult Questions About Its Vaccine
Some trial participants only got a partial dose of AstraZeneca’s vaccine. Experts said the company’s spotty disclosures have eroded confidence.
By Rebecca Robbins and Benjamin Mueller Nov. 25

A Russian vaccine maker reports positive results based on an incomplete trial.
The results were based on an unspecified small group of volunteers during the ongoing Phase 3 trial of the vaccine.
By Andrew E. Kramer


Washington Post
Opinion by Editorial Board
The U.S. has ensured its supplies of coronavirus vaccine. Now it must help provide them to poor
Nov 26, 2020
THE WORLD HEALTH Organization’s director-general, Dr. Tedros Adhanom Ghebreyesus, warned in August that no country could afford to go it alone in fighting the pandemic. Nations already depend on global supply chains for everything from diagnostic testing to personal protective equipment, he said, and they must avoid “vaccine nationalism” when it comes to the most powerful tool to fight covid-19. When the Group of 20 leaders held their virtual summit meeting last weekend, they again declared their intent not to hoard lifesaving vaccines, saying, “We will spare no effort to ensure their affordable and equitable access for all people.”

But as vaccines come closer to reality, wealthy nations of the world have already taken care of their own needs and signed contracts to buy up hundreds of millions of vaccine doses. And the poor? A global risk-sharing procurement initiative to ensure fair and equitable access to vaccines, the Covax Facility, could bring them protection, but only if it can get sufficient funding in 2021. This is the world’s best chance to help the poorest populations confront the pandemic, being led by the WHO, the Coalition for Epidemic Preparedness Innovations and Gavi, the Vaccine Alliance.

As it currently stands, 92 lower-income economies will be supported by the financing mechanism in Covax, the Advanced Market Commitment (AMC). Ninety-seven higher-income economies have signed up as self-financing members of the Covax Facility. The idea is to pool vaccine buying power and ensure distribution for all countries, including the less developed nations, with a goal of obtaining 2 billion doses to protect 20 percent of their populations by the end of 2021, enough to cover front-line health-care workers and the most vulnerable. Negotiations for the shots are underway with manufacturers. To make this initiative work, according to the WHO, there is an urgent need for $7.8 billion next year from international donors, including $5 billion for the 92 lower-income countries, and additional funds to help them set up distribution systems, a demanding task. All of that funding remains to be raised.

China and Russia are developing vaccines, too. They have their own national regulatory process, but for their vaccines to be used globally through the Covax Facility they would have to meet international standards through WHO review of quality, safety and impact on disease. They could distribute the vaccines on their own. China has joined Covax as a participant, allowing it to procure doses from the facility, but Russia has not.

Among the big donors to the AMC are the United Kingdom, Canada, Germany and Saudi Arabia. President-elect Joe Biden should commit the United States, too. A $200 million donation would amount to only 2 percent of spending on Operation Warp Speed. And we hope Mr. Biden will rapidly return the United States to the WHO.

The world’s wealthiest countries are on the verge of a science triumph with the arrival of an effective vaccine in less than a year. But in this moment of need, the haves should also extend a hand to the have-nots. As Dr. Tedros said in August, “No one is safe until everyone is safe.”

EU says first virus vaccinations possible by Christmas
Associated Press · Nov 25, 2020